Health Care [ 4/12 ] | Biotechnology [ 20/74 ]
NASDAQ | Common Stock
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis.
It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.
Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 25 | -0.65 Decreased by -27.45% | -0.66 Increased by +1.68% |
| Mar 19, 25 | -0.65 Decreased by -41.30% | -0.63 Decreased by -3.77% |
| Nov 7, 24 | -0.62 Decreased by -67.57% | -0.60 Decreased by -3.33% |
| Aug 8, 24 | -0.56 Decreased by -51.35% | -0.55 Decreased by -1.82% |
| May 15, 24 | -0.51 Decreased by -13.33% | -0.48 Decreased by -6.25% |
| Mar 21, 24 | -0.46 Increased by +11.54% | -0.39 Decreased by -17.95% |
| Nov 9, 23 | -0.37 Increased by +5.13% | -0.40 Increased by +7.50% |
| Aug 10, 23 | -0.37 Increased by +17.78% | -0.44 Increased by +15.91% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -35.94 M Decreased by -43.50% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -32.59 M Decreased by -56.02% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -30.63 M Decreased by -86.22% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -27.60 M Decreased by -90.53% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -25.05 M Decreased by -57.99% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 4.01 M Increased by +N/A% | -20.89 M Decreased by -40.37% | Decreased by -520.85% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -16.45 M Decreased by -48.50% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -14.49 M Decreased by -13.53% | Decreased by N/A% Decreased by N/A% |